Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

rocapuldencel-T

- PMLiVE

Pre-chemotherapy indication for Xtandi in prostate cancer

Astellas drug set to compete with J&J’s Zytiga

- PMLiVE

Pharma spent $342m on journal advertising in first half of 2014

J&J led spending and Invokana was most advertised brand

National Institute for Health and Care Excellence NICE logo

NICE wants greater access to clinical data

Will turn to European regulators if companies fail to provide information

- PMLiVE

Merck brings first PD-1 inhibitor to US market

FDA approves Keytruda for advanced melanoma

- PMLiVE

England’s Cancer Drugs Fund: Naughty or NICE?

The decision to extend the CDF raises questions on the future of cancer drug access on the NHS

dengue fever mosquito

Sanofi: positive trial sets up dengue vaccine filings

Could help prevent mosquito-borne fever that is endemic in Latin America and Asia

- PMLiVE

AZ and Redx collaborate on genetics of cancer

Research will take place at Alderley Park site

- PMLiVE

GSK Ebola vaccine to start safety studies

Will use volunteers in the US, UK and Africa

- PMLiVE

Rapid review for Pfizer’s superbug vaccine

FDA to expedite assessment of Clostridium difficile inoculation

- PMLiVE

Major depression in UK cancer patients going untreated

Only 17% of patients reacted to usual NHS therapy according to new research

- PMLiVE

Pfizer and Merck expand anti-PD1 cancer alliance

Will investigate combination of pembrolizumab and Xalkori

- PMLiVE

Merck and Advaxis to study anti-PD1 combo

Collaboration to investigate pembrolizumab and ADXS-PSA in prostate cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links